Mirum Pharmaceuticals (NASDAQ:MIRM) Director Laura Brege Sells 14,167 Shares of Company Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Laura Brege sold 14,167 shares of the stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $94.21, for a total value of $1,334,673.07. Following the completion of the sale, the director directly owned 15,703 shares in the company, valued at $1,479,379.63. This represents a 47.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM traded up $0.63 during midday trading on Friday, hitting $93.96. 321,083 shares of the stock traded hands, compared to its average volume of 831,114. Mirum Pharmaceuticals, Inc. has a 1-year low of $63.23 and a 1-year high of $130.00. The firm has a market capitalization of $6.13 billion, a PE ratio of -6.07 and a beta of 0.75. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.98 and a current ratio of 2.07. The business’s 50 day moving average price is $88.92 and its two-hundred day moving average price is $98.44.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. The firm had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. During the same quarter in the prior year, the company posted $0.05 EPS. The firm’s revenue was up 39.6% on a year-over-year basis. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. HighVista Strategies LLC raised its position in shares of Mirum Pharmaceuticals by 79.0% during the 3rd quarter. HighVista Strategies LLC now owns 26,660 shares of the company’s stock worth $2,279,000 after buying an additional 11,768 shares in the last quarter. Bleakley Financial Group LLC bought a new position in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $1,128,000. Impax Asset Management Group plc acquired a new position in shares of Mirum Pharmaceuticals during the third quarter valued at approximately $8,548,000. Ground Swell Capital LLC acquired a new position in shares of Mirum Pharmaceuticals during the third quarter valued at approximately $564,000. Finally, Virtus Advisers LLC increased its stake in shares of Mirum Pharmaceuticals by 16.1% during the third quarter. Virtus Advisers LLC now owns 4,761 shares of the company’s stock valued at $407,000 after acquiring an additional 661 shares during the period.

Wall Street Analyst Weigh In

Several research firms have commented on MIRM. UBS Group set a $137.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Cantor Fitzgerald raised their price target on shares of Mirum Pharmaceuticals from $155.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, November 4th. Stifel Nicolaus lifted their price target on Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 6th. Finally, Citizens Jmp lifted their target price on Mirum Pharmaceuticals from $144.00 to $167.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $155.56.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.